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We appreciate the helpful comments by Dr. Rogers but
with all due respect there are a number of problematic
issues with his remarks on our most recent publication
[1]. Firstly, while we agree that nutritional epidemiology
is extremely challenging, particularly on the scale and
population herein, we must emphasize that the data
speak by themselves. Indeed, the rigorous statistical ap-
proach argues for the potentially detrimental effects of
monosodium glutamate (MSG) on this target popula-
tion. Second, our observation is supported by recent ani-
mal data which, albeit with differences related to
experimental models and dosage proportions, suggest a
contribution of MSG to the worldwide epidemics of
obesity, metabolic syndrome, diabetes and non-alcoholic
steatohepatitis (NASH) [2-7]. It is well-established that
obesity can be induced by an injection of MSG to new
born rodents. Third, we note that data from one of the
studies considered as negative by Dr. Rogers [8] reported
a larger waist circumference, a crucial parameter of the* Correspondence: ubocha@kku.ac.th
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reproduction in any medium, provided the ormetabolic syndrome, and an elevated prevalence of cen-
tral obesity associated with the highest quartile of MSG
intake, in an analysis similar to our approach. Moreover,
results of a cohort study from the same group also sug-
gested the potentially negative impact of MSG on
human health; MSG intake was associated with a signifi-
cant increase in systolic and diastolic blood pressure [9].
High blood pressure is one of the five criteria of ATPIII
for the diagnosis of metabolic syndrome. Fourth, we
agreed that there is inconsistency of the results of epi-
demiological studies on MSG intake and overweight
which is always observed in epidemiological research
field. So far, there are 3 studies showed the positive asso-
ciation and one study showed negative association of
MSG intake and overweight. Fifth, the questionable
points by Dr. Rogers are responded as follow;
1) The number of participants (n = 315) in Pethlert et.
al, 2011[10] is not the same as Insawang et. al, 2012
(n = 349) because it is different project and time
setting. Pethlert project was run after Insawang
project. Not all participants in Insawang project were
recruited into Pethlert project. Though the
participants were the same group, some participantsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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such as unavailable during study period, did not
return the informed consent, the levels of daily
alcoholic drinking were exceeded the criteria of non-
alcoholic fatty liver. Therefore, the number of
Pethlert project is less than Insawang project.
2) Commercial MSG is always available and is not
expensive for villagers to obtain it. Normally, only
one person preparing food for family and that is the
key person for MSG consumption in the family. We
gave enough information to participants including
key persons about the use and the objective of MSG
measurement. Participants knew that it doesn’t
matter how much the MSG left in the provided box,
it will belong to them after 10-day of study.
Therefore, it is unlikely that individuals use more
MSG than usual because it is free.
3) Nowadays, it becomes a nuclear family in Thailand,
including the area of study. Some families do not
have children below 10 years old; however, some
families have one or two children. Families usually
prepare a special meal for young children by
avoiding chili, MSG, salty or any spicy ingredients.
Thus, it is not suitable to divide the MSG
consumption in each family by number of all family
members which may include infant, toddler, or pre-
school children. Therefore, we excluded children
under 10 for more reasonable calculation of
individuals MSG consumption.
4) The association of the median and percentage values
of the five criteria of ATP III individually and MSG
intake were not observed in our study. This is
probably due to the small number in sample size.
However, when combined the metabolic disorders as
a cluster, the association was found. Every 1-g of
MSG intake significantly increased the risk of having
metabolic syndrome with the odds ratio of 1.14. In
other word, the estimated risk of having metabolic
syndrome increased 1.14 fold for each gram of daily
MSG consumption. If a person consumed MSG 5 g/
day the estimated risk of having metabolic syndrome
would be increased 5.7 fold. Therefore, it shall not
classify as very week association.
5) It is barely to find non-MSG users in the area of
study. Moreover, it is hard to identify a person with
non-MSG user because if he/she eats out or buys
food from retailer or restaurant; generally he/she
cannot avoid MSG exposure. Therefore, non-MSG
users were not included in our study.
Finally, we note that none of the investigators in our
paper has any industrial or personal disclosure.Conclusion
We submit that MSG poses a host risk in susceptible
individuals and that further data is needed to define
those at risk.
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